Reverse Engineering of the Selective Agonist TBPB Unveils Both Orthosteric and Allosteric Modes of Action at the M1 Muscarinic Acetylcholine Receptor
- 1 September 2013
- journal article
- research article
- Published by Elsevier in Molecular Pharmacology
- Vol. 84 (3) , 425-437
Abstract
Recent interest in the M1 muscarinic acetylcholine (ACh) receptor (mAChR) has led to the discovery of various selective agonists for the receptor. The novel selective agonist 1-(1′-(2-methylbenzyl)-1,4′-bipiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-1 (TBPB) displays unprecedented functional selectivity at the M1 mAChR. This functional selectivity has been described to stem from sole interaction with an allosteric site, although the evidence for such a mechanism is equivocal. To delineate TBPB’s mechanism of action, several truncated variants of TBPB were synthesized and characterized. Binding experiments with [3H]N-methylscopolamine at the M1, M2, M3, and M4 mAChRs revealed radioligand displacement in a manner consistent with a competitive binding mode at the orthosteric site by TBPB and fragment derivatives. Cell-based functional assays of fragment derivatives of TBPB identified both agonistic and antagonistic moieties, one of which, 1-(1-cyclohexylpiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-1 (VCP794), lost agonistic selectivity for the M1 mAChR. Further interaction experiments between TBPB or its antagonist fragments with ACh also indicated a mechanism consistent with competitive binding at mAChRs. However, interaction with an allosteric site by an antagonist fragment of TBPB was demonstrated via its ability to retard radioligand dissociation. To reconcile this dual orthosteric/allosteric pharmacological behavior, we propose that TBPB is a bitopic ligand, interacting with both the orthosteric site and an allosteric site, at the M1 mAChR. This mechanism may also be the case for other selective agonists for mAChRs, and should be taken into consideration in the profiling and classification of new novel selective agonists for this receptor family.Keywords
This publication has 44 references indexed in Scilit:
- Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assaysBritish Journal of Pharmacology, 2010
- Orthosteric and Allosteric Modes of Interaction of Novel Selective Agonists of the M1 Muscarinic Acetylcholine ReceptorMolecular Pharmacology, 2010
- NovelN-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1mAChR AgonistsACS Medicinal Chemistry Letters, 2010
- Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moietiesBioorganic & Medicinal Chemistry Letters, 2008
- Allosteric modulation of the muscarinic M4receptor as an approach to treating schizophreniaProceedings of the National Academy of Sciences, 2008
- ALLOSTERIC INTERACTIONS AT MUSCARINIC CHOLINOCEPTORSClinical and Experimental Pharmacology and Physiology, 1998
- Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer DiseaseArchives of Neurology, 1997
- Binding of the muscarine receptor antagonist heptane-1,7-bis(dimethyl-3′-phthalimidopropyl) ammonium bromide at cholinoceptor sitesEuropean Journal of Pharmacology: Molecular Pharmacology, 1993
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973
- SOME QUANTITATIVE USES OF DRUG ANTAGONISTSBritish Journal of Pharmacology and Chemotherapy, 1959